INTRODUCTION
The demand for knockout technology in developmental biology is rising exponentially as genes of interest emerge at an ever-increasing rate from genomic studies, and therefore the central task becomes to relate genes to functions. Historically, lengthy mutant screens in Drosophila, and Caenorhabditis elegans have provided us with most of our knowledge of gene function in development, but reverse genetic approaches have become increasingly attractive, because they offer the possibility of taking interesting candidate genes from genomic databases and speedily identifying their roles.
Against this background, it is not surprising that the introduction of a new loss-of-function technology has been met with enthusiasm by developmental biologists. Morpholino antisense oligos were first developed for clinical therapeutic applications, where previous antisense approaches had proven seriously flawed (Summerton and Weller, 1997) . They were first introduced into developmental biology early in 2000 (Heasman et al., 2000) and have since been used by researchers in a range of model organisms, including sea urchin (Howard et al., 2001) , Ciona savignyi (Satou et al., 2001) , Xenopus laevis (Audic et al., 2001; Schweickert et al., 2001; , Xenopus tropicalis (Nutt et al., 2001) , zebrafish (Nasevicius and Ekker, 2000; Bauer et al., 2001; Ross et al., 2001; Segawa et al., 2001; Shepherd et al., 2001; Yang et al., 2001 , and 19 papers in Genesis 30, July 30, 2001), chick (Kos et al., 2001) , and mouse (Coonrod et al., 2001) . In the summer of 2001, an entire issue of the journal "Genesis" was dedicated to articles studying gene function in development using this technique. As the first wave of usage is well underway, the aim of this review is to survey the successes and limitations of this latest loss-of-function tool.
Morpholino Oligos Block Messenger mRNA Translation
First generation antisense oligos were designed as short stretches of DNA (18 -22 mers) that form RNA-DNA hybrids with the target mRNA and act as substrates for RNAse H to degrade the mRNA (Cazenave et al., 1989) . The target mRNA is cleaved by RNAse H, and the fragments are subsequently broken down by nuclease activity. DNA oligos have had very limited applicability in developmental studies, both because they have nonspecific toxic side effects, (Heasman et al., 1991) and because degraded mRNAs are continually replaced by new transcription, making continued treatment with oligo a necessity. The one exception to this general case is that of loss-of-function studies of maternal genes in Xenopus embryos (Zuck et al., 1998) . Here, antisense oligos are injected into the oocyte, which is then cultured for several days before fertilization. The oligos degrade the target mRNA, and are themselves broken down, so that they have no toxic effect on the embryos after fertilization. This, together with the fact that there is no transcription in the developing Xenopus embryo until the 4000-cell stage, makes DNA oligos a feasible approach for functional analysis in this restricted area (Heasman et al., 1994; Zhang et al., 1998) .
Morpholino oligos were designed specifically to overcome many of the limitations of regular DNA oligos (Gene Tools, LLC). Recognizing that RNAse H-mediated degradation was not the only efficient way to prevent translation, Summerton and Weller (1997) developed a DNA analog that acts by blocking translation. This analog has the riboside moiety of each subunit converted to a morpholine moiety (morpholine ϭ C 4 H 9 NO), and uses a phosphorodiamidate intersubunit linkage instead of phosphorodiester linkages (see Summerton and Weller, 1997 for a detailed description). Morpholino oligos only block translation when they are designed to be complementary to the 5Ј leader sequences, or to the first 25 bases 3Ј to the AUG translational start site, and it is presumed that they act by preventing ribosomes from binding. In cell-free translation experiments, they were shown to have greater efficiency and specificity than other antisense oligos, and tests showed excellent solubility and stability characteristics (Summerton, 1999) . Because the 5ЈUTR is less conserved than coding regions, the chance of the morpholino oligo blocking incorrect mRNAs nonspecifically is less than for traditional oligos. Their increased specificity also derives from the fact that translation is not blocked when there are several mismatched nucleotides. For most effective RNA targeting, oligos are recommended to be 25 mers in length, and have little self-complementarity (four or fewer contiguous intrastand base pairs). Water solubility is maintained by using less than 36% guanine content and no runs of more than triplets of GGG (Gene Tools, LLC).
The next critical phase for the development of morpholino oligos as loss-of-function tools in developmental studies has been to test them in embryos.
Morpholino Injections Phenocopy Known Mutants
The critical questions to answer for testing morpholino oligos' reliability as loss-of-function tools are, first, whether they mimic the phenotypes of known mutants, and if so, how reproducible or penetrant the effects are. Of equal importance in the development of morpholinos as tools to study novel gene function is to recognize toxic side effects of oligo injection, to avoid the trap of confusing those effects with those caused by true loss-of-function. A third important consideration in deciding whether morpholinos could be useful in studying genes acting during organogenesis is how long after injection they actively block translation.
Most published work to date testing morpholinos has been carried out on zebrafish embryos, where many mutants are available that have defined the roles of genes important for development. In fish embryos, oligos are typically injected at the one-to four-cell stage into the cytoplasm or yolk. Table 1 is a partial list of the genes that have been studied by their loss-of-function both in mutants and in morpholino-injected embryos. Clearly, this represents the most positive view of the success of the morpholino approach since injections which do not phenocopy mutants are much less likely to be published. However, in two papers, the success rate of tested genes was reported. Lele et al. (2000) report a 100% success rate for 7/7 genes (swirl, snailhouse, somitabun, minifin, silberblick, pipetail, and lost-a-fin) , while Nasevicius and Ekker (2000) report a 100% success rate for all nine genes studied (including no tail, chordin, one-eyed-pinhead, nacre, and sparse) . This provides very substantial encouragement for pursuing this antisense approach.
However, these data also highlight several characteristics of morpholino-induced phenotypes, most importantly, the variability of the severity of the phenotypes and the nonspecific side effects caused by oligo injection.
Variability in the Severity of Phenotypes
An important consideration in the use of morpholinos is the extent to which they give consistent results when one dose is injected into a group of embryos. Importantly, injections of a morpholino complementary to GFP mRNA reduced GFP protein expression in all cells of fish expressing a GFP transgene, indicating that, at least in this case, the morpholino spread evenly throughout the zebrafish embryo after injection (Nasevicius and Ekker, 2000) . In some cases, extremely consistent results have been reported for oligo effectiveness. For example, a bmp7 oligo causes extreme dorsalization at final concentrations of 1 and 4 M in 81 and 93% of cases, respectively (Imai and Talbot, 2001) . A 5.4 M final concentration of chordin oligo phenocopies the chordin null mutant embryo in more than 75% of cases (Nasevicius and Ekker, 2000) , and no tail is phenocopied in 98% (Nasevicius and Ekker, 2000; using 10.8 M) and 100% of cases (Feldman and Stemple, 2001 ; using 2.1-8.6 M final concentration). For no tail, this correlates with a complete lack of protein on a Western blot (Nasevicius and Ekker, 2000) . Bauer et al., 2001 For other targets, the results are much more variable. Smad 5 depletions, caused by a 6.5-ng dose, giving a final concentration of 7.8 M, resulted in 24% of embryos with a weak phenotype compared with the genetic mutant, somitabun, while 49% resembled the mutant and 27% had stronger effects . Higher doses than 6.5 ng caused nonspecific effects. One-eyed-pinhead morpholinoinjected embryos showed the expected phenotype in only 43% of cases (10.8 M), and the rest of the embryos were normal (Nasevicius and Ekker, 2000) . Thus, the potential variability in penetrance of the morpholino is an important consideration for interpreting data. While, in some instances, a graded series of phenotypes equivalent to an allelic series may be very beneficial for functional analyses, when novel genes are being studied, it may add to the uncertainty of what is real and what is a nonspecific side effect. This will be particularly true if the toxic dose is close to the effective dose.
A second variability to keep in mind when comparing morpholino-induced mutant phenotypes and genetic mutations, is that the morpholino derived mutant might lie anywhere on the entire spectrum of phenotypes caused by complete depletion of protein to only a slight reduction in protein levels. The degree of depletion will depend on many parameters, as well as oligo concentration, including the amount and stability of the protein that is present at the time of oligo introduction, the amount of diffusion, the localization of the targeted mRNA, and the amount of new transcription. In making meaningful comparisons with genetic phenotypes, it is also helpful to compare the morpholino phenotype with both null mutations and hypomorphic mutations. It is clearly possible for morpholinos to cause more severe phenotypes than hypomorphs, or null alleles that only affect zygotic gene products (e.g., Bauer et al., 2001) .
Side Effects of Morpholino Oligos
Since morpholino oligos were developed for delivery by scrape-loading into cells in tissue culture, no guidelines suitable for embryo injection were commercially available. Thus, researchers routinely injected a series of increasing doses of oligo into zebrafish embryos and examined them for both expected and unexpected phenotypes. In typical experiments, 1 nl of a range of concentration of oligo (0.1-0.8 mM; with a final concentration of 1-8 M) was injected into the yolk of genetically wild-type embryos at the one-cell stage. Several authors report that, at the high end of this range, nonspecific effects occur. These include widespread cell death (Braat et al., 2001; Lele et al., 2001) , defects in epiboly, (Imai and Talbot, 2001) , and neural degeneration (Nasevicius and Ekker, 2000; Karlen and Rebagliati, 2001 ), effects that would not be expected from genetic mutants in which the genes are completely inactivated.
Why morpholinos cause side effects is a major question that remains to be resolved. Clearly, the likely possibilities are either that there are nonspecific effects of morpholino oligos or contaminants, or that there are effects due to unexpected complementarity of the oligo to other unknown genes. The appearance of these effects is highly oligodependent. For example, two groups compared the depletion of bmp2b protein using different morpholinos. One oligo, complementary to Ϫ61 to Ϫ37 of the 5ЈUTR of bmp2b sequence caused the specific dorsalized swirl phenotype in 80% of cases at final concentrations of 0.4 M, but caused nonspecific epiboly defects and lysis when 1 M was injected (Imai and Talbot, 2001) . In contrast, a second oligo, designed against Ϫ4 to ϩ19, phenocopied the swirl mutant at 3.8 M, and only caused cell death at doses higher than this ). This difference is not due to variability in calibrating the dose used, since both groups also targeted bmp7, this time using the same oligo and having comparable results.
Since it has not been resolved whether side effects are nonspecific or due to the morpholino being complementary to an unknown target, controls for both possibilities are incorporated into most published work (see below).
Oligo Stability
Since morpholino oligos are DNA analogs, they are not susceptible to enzymatic degradation (Hudziak et al., 1996) , unlike DNA oligos, and thus have much higher biological stability. This makes it feasible to target genes expressed during organogenesis by injecting oligos into the one-to two-cell-stage embryo. In the case of the vasa gene, its protein could not be detected by confocal microscopy 4 days after the initial injection of 12 M final concentration (1 ng) of morpholino oligo (Braat et al., 2001 ). Nasevicius and Ekker (2000) , studying the loss of body pigmentation with a nacre morpholino, noted nearly complete loss of pigment through 2 days of development. Similarly, morpholinoinjected embryos phenocopied the colourless mutant in having reduced melanophores after 48 h of development. Here, the oligo-derived mutants were never as complete as the strongest cls mutants, since some melanophores were always present (Dutton et al., 2001) .
Presumably, oligos eventually lose effectiveness by dilution. Clearly, the length of the loss-of-function effect of an injected oligo depends on the transcription and translation characteristics of the targeted mRNA, as well as the dose of oligo, and will need to be determined for each gene of interest.
How Widely Applicable Are Morpholino Oligos?
Morpholinos have been used in several model organisms in loss-of-function studies. In Xenopus, we have routinely used DNA oligos to study maternal gene function, and have, in several cases, compared the effectiveness of morpholinos and DNA oligos. We find there are clear advan-tages and disadvantages of both approaches. DNA oligos' efficacy can be very easily measured, by comparing the amount of RNA left in control and experimental oocytes after oligo injection, using either PCR or Northern analysis. In comparison, morpholinos do not degrade RNA, and their activity needs to be confirmed in other ways, generally by Western blotting or immunostaining, and antibodies are not always available. Another approach to show their activity is to inject a GFP-tagged version of the mRNA and to show that the oligo reduces GFP fluorescence (Yang et al., 2001) . One limitation of this is, however, that the endogenous mRNA and injected version may not have the same accessibility to the morpholino, and so this control does not guarantee that the oligo will have the same effect on the endogenous mRNA.
A clear advantage of morpholinos is that they can be injected directly into fertilized eggs without the toxic effects associated with DNA oligos. For example, when a morpholino oligo against the Wnt pathway component, ␤ catenin, was injected at the two-cell stage, it caused complete loss of axial structures, mimicking the effect of a phosphorodiester/phosphorothioate oligo injected into the oocyte (Heasman et al., 2000) . The effective dose in this case (5-10 ng; 0.6 -1.2 M final concentration) is very similar to the typical doses used in zebrafish studies. Thus, as long as there is no stored pool of protein, morpholinos can effectively block maternal gene function.
Another perceived advantage of morpholinos is that, since they only work by targeting the start site of the mRNA, it is easier to design an effective oligo. For DNA oligos, five or six oligos are typically tested to find the most efficient one. However, morpholino oligos cannot simply be assumed to be consistently effective. In those cases where more than one oligo has been designed to be complementary to different parts of the 5ЈUTR sequence of a target mRNA, the oligos have had different degrees of effectiveness in blocking translation (Imai and Talbot, 2001; . This suggests that, as for DNA oligos, we are ignorant of many of the variables underlying morpholino activity.
As in zebrafish studies, it is clear that morpholino oligos may cause side effects in Xenopus, and that as the dose increases, the possibility of nonspecific abnormalities also rises. Thus, it is not possible to rely solely upon a dose response for revealing a specific phenotype (Audic et al., 2001) . Abnormalities include anterior/posterior truncations, microcephaly, (Nutt et al., 2001) , slowed cleavage, delayed development, and widespread cell death (unpublished observations). In some cases, the toxic dose can be clearly distinguished from the effective dose. Nutt et al. (2001) found that 1 ng (1.2 M final concentration) of morpholino against GFP caused complete inhibition of GFP fluorescence in transgenic embryos carrying an integration of the CMV-GFP transgene, while 40 ng (4.8 M final concentration) was injected to cause 45% of the embryos to develop abnormally. In other cases, specific and nonspecific effects can only be distinguished by the use of appropriate controls.
One type of control frequently used both in Xenopus and zebrafish studies is to inject other morpholino oligos, either a nonsense morpholino oligo, an invert of the antisense oligo or a mismatched oligo. These cannot control for the possibility that the experimental oligo is binding to an unexpected mRNA, since they do not have the same sequence. An even worse control is to use the sense oligo, since this should clearly bind to the antisense oligo and block its activity, whether or not that activity is specific. Thus, these types of controls only control for nonspecific toxic contaminants (if they were synthesized at the same time and with the same reagents, machine, and personnel as the experimental oligo).
For DNA antisense oligos, that act by degrading mRNA, specificity can be tested directly, by injecting synthetic mRNA into oocytes after the endogenous mRNA has been degraded by the oligo, and testing its ability to rescue the phenotype. A similar control is necessary for morpholino experiments. However, if the injected mRNA has the 5Ј sequence complementary to the oligo, it will bind to the oligo and prevent its activity directly, by competing for binding to the endogenous mRNA. This is not a good control for specificity. A better control is to use an mRNA that either lacks the 5Ј UTR recognized by the oligo (Heasman et al., 2000; Nasevicius and Ekker 2000; Bauer et al., 2001; Satou et al., 2001) , or has third base modifications, so that it is no longer recognized by the oligo (Cui et al., 2001) . Unfortunately, rescue experiments are often plagued themselves with complications due to the incorrect distribution and activity of the injected mRNA ). An alternative approach may be to use two different morpholino oligos to target the mRNA (Howard et al., 2001; , and ask if they cause the same phenotype.
Another consideration specific to X. laevis is that its allotetraploidy means there are often two orthologs of the gene of interest. These are generally very similar in the coding sequence, but have significant differences in the 5ЈUTR. So, to target both orthologs, morpholinos have to be designed either to complement the conserved coding region at the start site, or two oligos need to be made ). The related frog, Xenopus tropicalis, has a diploid genome, and is also amenable to morpholinos (Nutt et al., 2001) and thus may become a more popular model than X. laevis for morpholino studies.
Morpholinos have also been tested in ascidian (Satou et al., 2001 ) and mouse oocytes (Coonrod et al., 2001) , and shown to phenocopy the expected phenotypes for loss-offunction of the ␤ catenin and mos genes, respectively. In both sea urchin and chick embryos, morpholinos have been used to study novel gene function, and in each case, several lines of evidence, as well as the morpholino data were presented to confirm the conclusions (Howard et al., 2001; Kos et al., 2001) . Thus, for organisms that have typically lagged behind the genetic model organisms in loss-of-function assays, morpholinos offer a welcome additional approach.
CONCLUSIONS
In recent months, research on morpholinos has moved beyond the testing phase to the study of novel gene function. Because morpholinos do cause variable side effects and do have variable penetrance, embryos injected with morpholinos may have phenotypes that are difficult to interpret. The loss-of-function effects of morpholinos have to be supported by control mRNA rescue experiments, or, if those experiments are inconclusive, (e.g., because the injected mRNA has pleiotropic effects), by evidence that two morpholinos complementary to different parts of the 5ЈUTR have the same effect, or by evidence from other overexpression and/or underexpression studies (Ross et al., 2001; Shepherd et al., 2001) . In a recent study, for example, two morpholino oligos directed against the zebrafish type 1 serine/threonine kinase receptor Alk8, caused a dorsalized phenotype. This was partially rescued by an injected mRNA lacking the 5ЈUTR sequence targeted by the morpholinos. The authors went on to show that Alk 8 is disrupted in partially dorsalized lost-a-fin mutants, and that the mutant is also rescued by Alk8 mRNA, but not by mRNA for BMPs2 b or 7 (Bauer et al., 2001) . Together, the data prove the requirement for Alk 8 in the BMP-signaling pathway in zebrafish.
A second example of the use of morpholinos is described by Deardorff et al. (2001) . A morpholino directed against a Xenopus Wnt receptor Xfz3 was used to test the role of Xfz3 in neural crest formation. The effectiveness of the oligo in blocking translation was shown by Western blotting with an Xfz3-specific antibody. Its ability to block signal transduction was tested in explant assays, by comparing the up-regulation of Xslug by Xwnt 1, in the presence or absence of the MO. The effect of the morpholino oligo was then tested in whole embryos by injecting the oligo into cells fated to form neural crest, i.e., dorsal animal cells at the 32-cell stage. The oligo inhibited neural crest formation and this was rescued by coinjection with mouse Xfz3 mRNA (Deardorff et al., 2001) .
In both these cases, the phenotype seen with the morpholino oligo was supported by other approaches, and there were clear expectations that guided the analysis. Far more challenging will be the use of morpholinos to study completely novel gene function, where there are no clues to distinguish real from nonspecific phenotypes. It will be necessary to have the complete open reading frame of the targeted gene in order to carry out rescue experiments.
In summary, morpholinos have had substantial testing in embryos. As with most injection experiments, they may cause side effects, and may cause an array of phenotypes that require careful interpretation. These drawbacks can be overcome by a variety of controls and by comparison with other loss-and gain-of-function results. The most important technical question to answer in their development is why higher doses of biologically inert morpholinos should have side effects. But, with cautious use and clear controls, morpholinos will certainly speed the flow of developmental gene function data.
